Researchers analyzed the effectiveness of B7-H3 targeted antibody-drug conjugates, including ifinatamab deruxatecan, for patients with previously treated small cell lung cancer. This type of analysis combines data from multiple studies to see how well a specific treatment works compared to others.
The findings show that these targeted therapies had an objective response rate of 54 percent and a disease control rate of 89 percent. In comparison, the standard benchmark drug topotecan showed lower rates of 18 percent and 65 percent, respectively. Patients receiving the B7-H3 targeted drugs saw a median progression-free survival of about 5.6 months.
While these results are promising for patients with small cell lung cancer, there are important safety considerations. The study noted that nearly all patients experienced some level of treatment-related side effects, and over 60 percent experienced more severe reactions. Because the comparison between specific drugs was not a direct head-to-head trial, these results should be viewed as an indicator of potential activity rather than a definitive proof of superiority.
